Patents by Inventor Beth Borowsky

Beth Borowsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020156265
    Abstract: This invention provides isolated nucleic acids encoding a mammalian GABABR2 polypeptide, an isolated GABABR2 protein, vectors comprising isolated nucleic acid encoding mammalian GABABR2 polypeptides, cells expressing mammalian GABABR1/R2 receptors, antibodies directed to an epitope on mammalian GABABR2 polypeptides or mammalian GABABR1/R2 receptors, nucleic acid probes useful for detecting nucleic acids encoding mammalian GABABR2 polypeptides, antisense oligonucleotides complementary to unique sequences of nucleic acids encoding mammalian GABABR2 polypeptides, nonhuman transgenic animals which express DNA encoding normal or mutant mammalian GABABR1/R2 receptors, as well as methods of screening compounds acting as agonists or antagonists of mammalian GABABR1/R2 receptors.
    Type: Application
    Filed: February 26, 2001
    Publication date: October 24, 2002
    Inventors: Kenneth A. Jones, Thomas M. Laz, Beth Borowsky
  • Publication number: 20020045742
    Abstract: This invention provides isolated nucleic acids encoding a mammalian GABABR2 polypeptide, an isolated GABABR2 protein, vectors comprising isolated nucleic acid encoding mammalian GABABR2 polypeptides, cells expressing mammalian GABABR1/R2 receptors, antibodies directed to an epitope on mammalian GABABR2 polypeptides or mammalian GABABR1/R2 receptors, nucleic acid probes useful for detecting nucleic acids encoding mammalian GABABR2 polypeptides, antisense oligonucleotides complementary to unique sequences of nucleic acids encoding mammalian GABABR2 polypeptides, nonhuman transgenic animals which express DNA encoding normal or mutant mammalian GABABR1/R2 receptors, as well as methods of screening compounds acting as agonists or antagonists of mammalian GABABR1/R2 receptors.
    Type: Application
    Filed: December 15, 1998
    Publication date: April 18, 2002
    Inventors: KENNETH A. JONES, THOMAS M. LAZ, BETH BOROWSKY
  • Patent number: 6368812
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: April 9, 2002
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
  • Patent number: 6329197
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: December 11, 2001
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith
  • Publication number: 20010023289
    Abstract: This invention provides isolated nucleic acids encoding a mammalian GABABR2 polypeptide, an isolated GABABR2 protein, vectors comprising isolated nucleic acid encoding mammalian GABABR2 polypeptides, cells expressing mammalian GABABR1/R2 receptors, antibodies directed to an epitope on mammalian GABABR2 polypeptides or mammalian GABABR1/R2 receptors, nucleic acid probes useful for detecting nucleic acids encoding mammalian GABABR2 polypeptides, antisense oligonucleotides complementary to unique sequences of nucleic acids encoding mammalian GABABR2 polypeptides, nonhuman transgenic animals which express DNA encoding normal or mutant mammalian GABABR1/R2 receptors, as well as methods of screening compounds acting as agonists or antagonists of mammalian GABABR1/R2 receptors.
    Type: Application
    Filed: March 27, 2001
    Publication date: September 20, 2001
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Kenneth A. Jones, Thomas M. Laz, Beth Borowsky
  • Patent number: 6287788
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: September 11, 2001
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
  • Publication number: 20010009766
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: July 23, 1997
    Publication date: July 26, 2001
    Inventors: JONATHAN A. BARD, BETH BOROWSKY, KELLI E. SMITH
  • Patent number: 6262246
    Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: July 17, 2001
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Christophe P. G. Gerald, Kenneth A. Jones, James A. Bonini, Beth Borowsky